Serge Belanger
Stock Analyst at Needham
(3.73)
# 871
Out of 4,413 analysts
199
Total ratings
45.32%
Success rate
8.16%
Average return
Main Sectors:
Top Industries:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Reiterates: Buy | $35 | $12.04 | +190.70% | 11 | May 1, 2024 | |
| XENE Xenon Pharmaceuticals | Reiterates: Buy | $62 | $41.88 | +48.04% | 8 | Apr 12, 2024 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | $16 | $8.62 | +85.72% | 11 | Apr 12, 2024 | |
| HRTX Heron Therapeutics | Reiterates: Buy | $5 | $2.36 | +111.86% | 12 | Apr 11, 2024 | |
| COLL Collegium Pharmaceutical | Reiterates: Buy | $40 | $37.58 | +6.44% | 19 | Apr 11, 2024 | |
| AMPH Amphastar Pharmaceuticals | Reiterates: Hold | n/a | $41.48 | - | 1 | Apr 10, 2024 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Buy | $12 | $4.39 | +173.66% | 7 | Apr 10, 2024 | |
| LQDA Liquidia | Reiterates: Buy | $28 | $13.07 | +114.23% | 17 | Apr 10, 2024 | |
| ESPR Esperion Therapeutics | Reiterates: Buy | $8 | $1.97 | +307.12% | 13 | Apr 10, 2024 | |
| EOLS Evolus | Reiterates: Buy | $22 | $12.27 | +79.30% | 8 | Apr 10, 2024 | |
| PCRX Pacira BioSciences | Reiterates: Buy | $45 | $26.80 | +67.91% | 17 | Apr 9, 2024 | |
| CRMD CorMedix | Reiterates: Buy | $10 | $5.25 | +90.48% | 10 | Apr 9, 2024 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $8 | $2.87 | +179.23% | 10 | Apr 9, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Buy | $66 | $42.40 | +55.66% | 6 | Apr 9, 2024 | |
| CYTK Cytokinetics | Reiterates: Buy | $108 | $62.92 | +71.65% | 11 | Apr 9, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $30 | $13.78 | +117.71% | 7 | Mar 20, 2024 | |
| CLSD Clearside Biomedical | Reiterates: Buy | $4 | $1.27 | +214.96% | 6 | Mar 13, 2024 | |
| VRCA Verrica Pharmaceuticals | Reiterates: Buy | $8 | $6.95 | +15.11% | 10 | Mar 1, 2024 | |
| RVNC Revance Therapeutics | Maintains: Buy | $20 → $18 | $3.78 | +376.19% | 14 | Feb 29, 2024 | |
| AKBA Akebia Therapeutics | Downgrades: Hold | n/a | $1.28 | - | 1 | Mar 31, 2022 |
KalVista Pharmaceuticals
May 1, 2024
Reiterates: Buy
Price Target: $35
Current: $12.04
Upside: +190.70%
Xenon Pharmaceuticals
Apr 12, 2024
Reiterates: Buy
Price Target: $62
Current: $41.88
Upside: +48.04%
Arcutis Biotherapeutics
Apr 12, 2024
Reiterates: Buy
Price Target: $16
Current: $8.62
Upside: +85.72%
Heron Therapeutics
Apr 11, 2024
Reiterates: Buy
Price Target: $5
Current: $2.36
Upside: +111.86%
Collegium Pharmaceutical
Apr 11, 2024
Reiterates: Buy
Price Target: $40
Current: $37.58
Upside: +6.44%
Amphastar Pharmaceuticals
Apr 10, 2024
Reiterates: Hold
Price Target: n/a
Current: $41.48
Upside: -
BioCryst Pharmaceuticals
Apr 10, 2024
Reiterates: Buy
Price Target: $12
Current: $4.39
Upside: +173.66%
Liquidia
Apr 10, 2024
Reiterates: Buy
Price Target: $28
Current: $13.07
Upside: +114.23%
Esperion Therapeutics
Apr 10, 2024
Reiterates: Buy
Price Target: $8
Current: $1.97
Upside: +307.12%
Evolus
Apr 10, 2024
Reiterates: Buy
Price Target: $22
Current: $12.27
Upside: +79.30%
Pacira BioSciences
Apr 9, 2024
Reiterates: Buy
Price Target: $45
Current: $26.80
Upside: +67.91%
CorMedix
Apr 9, 2024
Reiterates: Buy
Price Target: $10
Current: $5.25
Upside: +90.48%
Trevi Therapeutics
Apr 9, 2024
Reiterates: Buy
Price Target: $8
Current: $2.87
Upside: +179.23%
MoonLake Immunotherapeutics
Apr 9, 2024
Reiterates: Buy
Price Target: $66
Current: $42.40
Upside: +55.66%
Cytokinetics
Apr 9, 2024
Reiterates: Buy
Price Target: $108
Current: $62.92
Upside: +71.65%
Viridian Therapeutics
Mar 20, 2024
Maintains: Buy
Price Target: $30
Current: $13.78
Upside: +117.71%
Clearside Biomedical
Mar 13, 2024
Reiterates: Buy
Price Target: $4
Current: $1.27
Upside: +214.96%
Verrica Pharmaceuticals
Mar 1, 2024
Reiterates: Buy
Price Target: $8
Current: $6.95
Upside: +15.11%
Revance Therapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $20 → $18
Current: $3.78
Upside: +376.19%
Akebia Therapeutics
Mar 31, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.28
Upside: -